China-based pharmaceutical CDMO WuXi STA has completed the acquisition of a drug product manufacturing facility in Couvet, Switzerland, from Bristol-Myers Squibb, as announced earlier in the year. The site is WuXi STA’s first in Europe. It makes tablets and capsules.

Through this transaction, WuXi STA has increased its global presence to eight R&D and manufacturing sites across Asia, North America and Europe, including a pharmaceutical clinical and commercial manufacturing complex on a 78-hectare campus at Middletown, Delaware, that was announced in early July.

Chinese CDMO WuXi STA is to build a new pharmaceutical clinical and commercial manufacturing complex on a 78-hectare campus in Middletown, Delaware. This has been supported by the Delaware Prosperity Partnership, other state departments and local government bodies, and received grants from the Delaware Strategic Fund.